Polysaccharides from astragali radix restore chemical-induced blood vessel loss in zebrafish
© Hu et al; BioMed Central Ltd. 2012
Received: 9 December 2011
Accepted: 23 February 2012
Published: 23 February 2012
Astragali Radix has been used widely for the treatment of cardiovascular and cerebrovascular diseases, and to enhance endurance and stamina in traditional Chinese medicine (TCM) for over 2000 years. The polysaccharide constituents of Astragali Radix (ARP) are considered as one of the major constituents contributing to the multiple pharmacological effects of this medicinal plant. The purpose of the study is to evaluate the vascular regenerative activities of ARPs in a chemically-induced blood vessel loss model in zebrafish.
Blood vessel loss was induced in both Tg(fli-1a:EGFP)y1 and Tg(fli-1a:nEGFP)y7 embryos by administration of 300 nM VEGFR tyrosine kinase inhibitor II (VRI) for 3 h at 24 hpf (hour post-fertilization). Then, the blood vessel damaged zebrafish were treated with ARPs for 21 h and 45 h after VRI withdrawal. Morphological changes in intersegmental vessels (ISVs) of zebrafish larvae were observed under the fluorescence microscope and measured quantitatively. The rescue effect of ARPs in the zebrafish models was validated by measuring the relative mRNA expressions of Kdrl, Kdr and Flt-1 using real-time PCR.
Two polysaccharide fractions, P4 (50000 D < molecular weight & diameter < 0.1 μm) and P5 (molecular diameter > 0.1 μm), isolated from Astragali Radix by ultrafiltration, produced a significant and dose-dependent recovery in VRI-induced blood vessel loss in zebrafish. Furthermore, the down-regulation of Flk-1 and Flt-1 mRNA expression induced by VRI was reversed by treatment with P4.
The present study demonstrates that P4 isolated from Astragali Radix reduces VRI-induced blood vessel loss in zebrafish. These findings support the hypothesis that polysaccharides are one of the active constituents in Astragali Radix, contributing to its beneficial effect on treatment of diseases associated with a deficiency in angiogenesis.
KeywordsAngiogenesis Astragali Radix Polysaccharide Ultrafiltration Zebrafish
Angiogenesis plays an important role in a wide range of physiological processes, such as wound healing and fetal development. However, many diseases such as cancer, chronic inflammatory disease, diabetic retinopathy, macular degeneration and cardiovascular disorders are associated with dysregulation of angiogenesis, in which blood vessel formation is either excessive or insufficient. Improvement of endothelial cell function and the enhancement of angiogenesis after critical cardiac and skeletal muscle ischemia is critical, as neovascularization of ischemic tissues may be sufficient to preserve tissue integrity and/or function, and thus is therapeutic. Polysaccharides are naturally occurring polymeric carbohydrate structures formed of repeating units of mono- or di-saccharides joined together by glycosidic bonds. This group of natural compounds are present in many traditional Chinese herbs and are reported to have both pro-angiogenic [1, 2] and anti-angiogenic [3–6] activities. Our previous discovery of a pro-angiogenic herb called Angelica sinesis by zebrafish assay leading to development of a wound healing formulation for diabetic foot ulcer patients [7, 8].
Astragali Radix, the dried root of Astragalus membranaceus (Fisch) Bge. or Astragalus mongholicus Bge. (Fabaceae), has been used in traditional Chinese medicine (TCM) for centuries to enhance the immune system, increase stamina and endurance, and to treat cerebrovascular and cardiovascular diseases . In China, the herb is commonly known as "Huangqi", and was first recorded in Shen Nong's Materia Medica about two thousand years ago. The primary constituents of Astragali Radix include polysaccharides, triterpene saponins, flavonoids, amino acids and trace elements [10, 11]. Clinically, Astragali Radix is used as either a single herb or in a TCM formula in combination with other herbal medicines. As a single herb, it stimulates the formation of capillaries in the chick embryo chorioallantoic membrane, and induces the proliferation of human umbilical vein endothelial cells (HUVEC) [12, 13].
In our previous study, an extract of Astragali Radix containing flavonoids, saponins and polysaccharides stimulated angiogenesis involving the VEGF-KDR/Flk and PI3K-Akt-eNOS pathways . Calycosin, one of the major isoflavones in Astragali Radix, was found to promote angiogenesis in normal zebrafish , whereas astragaloside IV reduced chemically-induced blood vessel loss . However, there are no systematic and in-depth studies investigating the angiogenesis activities of fractionated polysaccharides from Astragali Radix (ARPs).
New opportunities for in vivo natural product discovery have arisen through the recent emergence of zebrafish as an effective model system for the identification of disease-relevant genes and bioactive small molecules . The primary advantages of zebrafish for drug discovery include their high genetic, physiologic, and pharmacologic similarity with humans [17, 18]. In particular, in vivo screening of the angiogenic effects of ARP in zebrafish provides a more physiologically relevant result compared to in vitro screening because polysaccharides are often subjected to modification by the gastrointestinal tract and drug metabolism systems in vivo. Also, our recent studies suggest a high similarity of phase I and phase II drug metabolism systems between zebrafish and mammals [19, 20]. In the present study, we have investigated the vascular effects of fractionated ARPs based on molecular size in zebrafish angiogenesis assays.
Materials and methods
All animal experiments were conducted according to the ethical guidelines of ICMS, University of Macau and the protocol was approved by ICMS, University of Macau prior to the initiation of the experiments.
Chemicals and reagents
Dimethyl sulfoxide (DMSO) was purchased from Sigma, St. Louis, USA. VEGFR tyrosine kinase inhibitor II (VTKI, VRI) was purchased from Calbiochem Company/EMD Chemicals Inc (Cat. No. 676481) and was dissolved in DMSO to form a 1 mg/mL solution. Purified water was prepared with a Milli-Q purification system from Millipore (Milford, USA).
Preparation and analysis of ARP fractions
The dry roots of Astragali Radix (3,000 g) were extracted twice with 30 L distilled water at 80°C for 2 hours, and then filtered to remove impurities. The aqueous extract was concentrated and applied to an HPD600 macroporous resin column for further separation. The column was eluted with 10 L of ethanol and the aqueous portion was collected by eluting with 12 L of water, and then precipitated by the addition of three volumes of 80% (v/v) ethanol, and the precipitate was left to stand overnight. The resultant precipitate was collected by centrifugation, and then dried under vacuum. This dried polysaccharide extract was re-dissolved in distilled water and treated with Sevag reagent (1:4 n-butanol:chloroform, v/v, 3000 mL × 5) to remove proteins. The deproteined polysaccharide fraction was further fractionated using ultrafiltration with a series of commercial ultrafiltration membranes (size 10 K, 30 K, 50 K and 0.1 μm, Millipore, USA), according to the molecular weight (MW) and diameter (DM) of the target polysaccharide fraction.
The total sugar content was determined by a modified phenol/sulfuric acid method  at each step, and the yields of each polysaccharide fraction were calculated. Furthermore, the number-average molecular weight (Mn) and the weight-average molecular weight (Mw) of the active ARP fractions with higher efficacy and potency (P4) were determined by gel permeation chromatography (GPC). The uronic acid content of P4 was also determined using the hydroxydiphenyl method as previously described . The monosaccharide units of P4 were analyzed by gas chromatography (GC), and several types of monosaccharides were used as reference standards.
Maintenance of zebrafish and its embryos
The zebrafish strains, including Tg(fli-1a:EGFP)y1 and Tg(fli-1a:nEGFP)y7, were maintained as previously described (Westerfield et al. 1995).
Zebrafish embryo collection and drug treatment
Zebrafish embryos were generated by natural pair-wise mating (3-12 months old) and were raised at 28.5°C in embryo medium. Healthy, hatched zebrafish were picked out at 24 hour post-fertilization (hpf) and distributed into a 12-well microplate (15 embryos per well). They were pretreated with 300 nM tyrosine kinase inhibitor II, one of the VEGF receptor inhibitors (VRI), for 3 h. After that, the VRI was washed out and replaced with either 0.1% DMSO (v/v) embryo medium, or increasing concentrations of each of the five ARP fractions for 45 h. The embryos receiving embryo medium only served as a vehicle control. The media of all treatment groups were refreshed every 24 h. Each experiment was repeated at least three times.
Morphological observation of zebrafish
At 48 hpf and 72 hpf, zebrafish were removed from microplates and observed for viability and gross morphological changes under a fluorescence microscope (Olympus IX81 Motorized Inverted Microscope, Japan) equipped with a digital camera (DP controller, Soft Imaging System, Olympus). Images were analyzed with Axiovision 4.2 and Adobe Photoshop 7.0.
Assessment of vascular changes
24 hpf Tg(fli-1a:EGFP)y1 zebrafish embryos were pretreated with VRI for 3 h. Then after treatments of ARPs for 21 h and 45 h, intersegmental vessels (ISVs) were assessed for pro-angiogenesis activity of ARPs. In the vehicle control group, ISVs can be seen sprouting and elongating dorsally up from the dorsal aorta (DA), and the posterior cardinal vein (PCV) below, to form a right and left pair of dorsal longitudinal anastamotic vessels (DLAVs) by 1.5 dpf . In the vehicle control group, ISVs observed sprouting and elongating from DA (and CA) or PCV to DLAV were defined as intactness. In VRI treatment groups (including the VRI-only treatment group and the ARP treatment groups), some of the ISVs observed sprouting from DA or PCV, but not forming a complete ISV, were defined as a defective. The integrity of twenty ISVs near the anus (ten ISVs in front of the anus and ten ISVs after the anus) in each individual zebrafish was measured. The percentage recovery was calculated as the total length of the selected ISVs in the treatment group over the total length of the selected ISVs in the vehicle control group. For example: A 100% percentage recovery indicated completed recovery of ISVs in the treatment group the same as that in the vehicle control group, whereas the VRI-only treatment group showing complete inhibition of ISVs was set as 0% percentage recovery. Twenty ISVs near the anus (10 ISVs in front of the anus and 10 ISVs after the anus) in each embryo were measured for total length. At least 10 larvae per group, over a series of 3 independent experiments, were evaluated. Percentage recovery is defined as the total length of the selected ISVs in the treatment group over the total length of the selected ISVs in the vehicle control group. In addition, the total number of endothelial cells in the ISVs of Tg(fli-1a:nEGFP)y7 zebrafish larvae were assessed by counting directly the number of nuclei of GFP-positive endothelial cells present in the twenty selected ISVs. Each green light point represents one endothelial cell (GFP+). Data are presented as the mean ± SD (n = 3),* P < 0.05, # P < 0.001.
Total RNA extraction, reverse transcription, and real-time PCR
The zebrafish embryos were treated at 24 hpf as described above. At 48 hpf, total RNA was extracted from 30 zebrafish embryos of each treatment group, using the RNeasy Mini Kit (Qiagen, USA) in accordance with the manufacturer's instructions. RNA was reverse transcribed to single-strand cDNA using SuperScriptTM III First-Strand Synthesis System for RT-PCR (InvitrogenTM, USA), followed by real-time PCR using the TaqManH Universal PCR Master Mix, and 250 nM custom TaqMan primers for zebrafish Kdrl, Kdr and Flt1 (Applied Biosystems, USA) in the ABI 7500 Real-Time PCR System (Applied Biosystems). The expression of Kdrl, Kdr and Flt1 was normalized to the amount of bactin1, using the relative quantification method described by the manufacturer.
The zebrafish bactin1 primers were 5'-CAAGATTCCATACCCAGGAAGGA- 3' (F) and 5'-CAAGATTCCATACCCAGGAAGGA- 3' (R) (Applied Biosystems, USA).
The zebrafish Kdrl (Flk1A) primers were 5'- GACCATAAAACAAGTGAGGCAGAAG- 3' (F) and 5'- CTCCTGGTTTGACAGAGCGATA- 3' (R) (Applied Biosystems, USA).
The zebrafish Kdr (Flk1B) primers were 5'- CAAGTAACTCGTTTTCTCAACCTAAGC- 3' (F) and 5'-GGTCTGCTACACAACGCATTATAAC- 3' (R) (Applied Biosystems, USA).
The zebrafish FLT1 primers were 5'-AACTCACAGACCAGTGAACAAGATC- 3' (F) and 5'-GCCCTGTAACGTGTGCACTAAA- 3' (R) (Applied Biosystems, USA).
Preparation of ARP fractions
Description of ARPs extracted from Radix Astragali
molecular weight (D) and diameter range (μm)
molecular weight < 10000
10000 < molecular weight < 30000
30000 < molecular weight < 50000
50000 < molecular weight &diameter < 0.1
diameter > 0.1
total sugar content (%)
maximum non-toxic dosage (μg/ml)
ARP fractions rescue VRI-induced blood vessel loss in zebrafish
P4 reverses the VRI induced down regulation of flk-1 and flt-1 mRNA expression
In order to confirm the vascular phenotypic effects of P4 observed in Figure 1, 2, 3, 4, total RNAs from different groups of zebrafish pre-treated with VRI (0.3 μM) for 3 h, and then treated with different concentrations of P4 (10, 30 and 100 μg/ml) after VRI withdrawal, were isolated and reverse transcribed to cDNA, and relative mRNA expressions of Kdrl, Kdr and Flt-1 were determined, using real-time PCR. Vascular endothelial growth factor receptor 1 (VEGFR1) is a protein that in zebrafish is encoded by the FLT1 gene . Its tyrosine protein kinase activity is important for the control of cell proliferation and differentiation. VEGFR2 (fetal liver kinase, also known as KDR and Flk-1) has a higher affinity for VEGF and is a major transducer of the VEGF signal in endothelial cells [26, 27]. Figure 7 represents the gene expression levels (data expressed in a log2 scale) of three key VEGFRs in 48 hpf zebrafish larvae that were pre-treated with 0.3 μM VRI for 3 h and then treated with P4 (10, 30, and 100 μg/ml) for 21 h after VRI withdrawal. P4 caused a significant increase in mRNA expression of Kdrl (2.31-fold at 10 μg/ml, P < 0.001; 2.25-fold at 30 μg/ml, P < 0.001; 2.58-fold at 30 μg/ml, P < 0.001), Kdr (2.67-fold at 10 μg/ml, P < 0.001; 2.71-fold at 30 μg/ml, P < 0.001; 2.85-fold at 100 μg/ml, P < 0.001) and Flt1 (1.77-fold at 10 μg/ml, P < 0.001; 1.63-fold at 30 μg/ml, P < 0.001; 1.96-fold at 100 μg/ml, P < 0.001). Thus, these results suggest that P4 reversed the down-regulation of the expression of several key angiogenesis genes involved in VRI-induced blood vessel loss in zebrafish.
Astragali Radix has been used as a single herb, or in combination with other Chinese herbal medicines, for the treatment of cardiovascular diseases and to enhance stamina and endurance for thousands of years, which prompted us to investigate the vascular protective effects of ARPs from Astragali Radix. In the present study, ARPs were isolated by ultrafiltration according to different molecular weight ranges, and evaluating their pro-angiogenesis effects using the live zebrafish angiogenesis assays.
The results demonstrated that the Astragali Radix polysaccharide fraction P4 (ranging from MW > 50,000 D and DM < 0.1 μm) and P5 (range: DM > 0.1 μm) reduced VRI-induced blood vessel loss in zebrafish models. Both the percentage recovery and the number of endothelial cells of ISVs increased significantly following treatments with P4 and P5 in both the transgenic Tg(fli-1a:EGFP)y1 and Tg(fli-1a:nEGFP)y7 zebrafish models as compared with the VRI-only treatment group. These findings indicate that P4 and P5 possess pro-angiogenic activity. Compared to P5, the ARP fraction P4 exhibited higher potency and efficacy.
The results also demonstrated that P4-treatments induced phenotypic change in VRI-induced blood vessel loss in the zebrafish model that were well validated by recovery of the mRNA expressions of a few key gene makers selected from angiogenesis signaling pathways. VEGF, also known as vascular permeability factor (VPF), was originally described as a potent angiogenic factor as well as an essential growth factor for vascular endothelial cells . The formation of new blood vessels is orchestrated by a variety of different proteins, including cell adhesion molecules, extracellular matric components and VEGFRs. Gene targeting experiments have provided insights into the functions of VEGFRs [29, 30]. Although inactivation of each individual VEGFR can cause embryonic lethality at mid-gestation, they have different functionality [31, 32]. VEGFR2 is the receptor that initiates the main signaling pathways activated by VEGF. While the main function of VEGFR1 appears to be in regulating the binding between VEGF and VEGFR2 . In this investigation, the results of real-time PCR illustrate that different concentrations (10, 30 and 100 μg/ml) of P4 reversed VRI-induced down-regulation of the expression of Kdrl, Kdr and Flt1 in the zebrafish model. These data confirmed the predominant involvement of these angiogenesis-specific targets in P4's rescue effect at ISVs in VRI-induced blood vessel loss in zebrafish, and further supported the hypothesis that these clear phenotypic changes were the result of the recovery of angiogenesis deficiency.
Angiogenesis deficiencies are associated with numerous human cardiovascular and cerebrovascular diseases (e.g., ischemic cardiac and cerebral problems). The work presented here shows that VRI-induced blood vessel loss in zebrafish in vivo mimics angiogenesis deficiencies associated with human disease conditions. Our in vivo data suggests that P4 exerted a rescue effect only in a damaged blood vessel disease model rather than in healthy zebrafish (data not shown). This strongly suggests that P4 may be a novel therapy for the restoration of angiogenesis deficiencies under pathophysiological conditions. In summary, these data suggest that P4 exerts its angiogenic effects by rescuing damaged blood vessels in zebrafish. They also indicate that ARPs are a major group of active constituents in Astragali Radix.
day(s) post fertilization
hour(s) post fertilization
Astragali Radix polysaccharide
- VTKI (VRI):
VEGFR tyrosine kinase inhibitor II
number-average molecular weight
weight-average molecular weight
Gel Permeation Chromatography
Posterior Cardinal Vein
Longitudinal Anastamotic Vessel
This study is supported by a grant from the Science and Technology Development Fund of Macau SAR (Ref. No.045/2007/A3, 058/2009/A2 and 014/2011/A1), Research Committee, University of Macau (Ref. No.UL017/09-Y1)
- Rodriguez-Martinez S, Cancino-Diaz ME, Miguel PS, Cancino-Diaz JC: Lipopolysaccharide from Escherichia coli induces the expression of vascular endothelial growth factor via toll-like receptor 4 in human limbal fibroblasts. Exp Eye Res. 2006, 83: 1373-1377. 10.1016/j.exer.2006.07.015.View ArticlePubMed
- Wang S, Zhang Z, Lin X, Xu DS, Feng Y, Ding K: A polysaccharide, MDG-1, induces S1P1 and bFGF expression and augments survival and angiogenesis in the ischemic heart. Glycobiology. 2010, 20: 473-484. 10.1093/glycob/cwp199.View ArticlePubMed
- Croci DO, Cumashi A, Ushakova NA, Preobrazhenskaya ME, Piccoli A, Totani L, Ustyuzhanina NE, Bilan MI, Usov AI, Grachev AA, Morozevich GE, Berman AE, Sanderson CJ, Kelly M, Di Gregorio P, Rossi C, Tinari N, Iacobelli S, Rabinovich GA, Nifantiev NE: Fucans, but not fucomannoglucuronans, determine the biological activities of sulfated polysaccharides from Laminaria saccharina brown seaweed. PLoS One. 2011, 6: e17283-10.1371/journal.pone.0017283.PubMed CentralView ArticlePubMed
- Xu Z, Chen X, Zhong Z, Chen L, Wang Y: Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med. 2011, 39: 15-27. 10.1142/S0192415X11008610.View ArticlePubMed
- Chen WY, Yang WB, Wong CH, Shih DT: Effect of Reishi polysaccharides on human stem/progenitor cells. Bioorg Med Chem. 2010, 18: 8583-8591. 10.1016/j.bmc.2010.10.016.View ArticlePubMed
- Yang L, Wang Y, Zhou Q, Chen P, Liu T, Xie L: Inhibitory effects of polysaccharide extract from Spirulina platensis on corneal neovascularization. Mol Vis. 2009, 15: 1951-1961.PubMed CentralPubMed
- Lam HW, Lin HC, Lao SC, Gao JL, Hong SJ, Leong CW, Yue PY, Kwan YW, Leung AY, Wang YT, Lee SM: The angiogenic effects of Angelica sinensis extract on HUVEC in vitro and zebrafish in vivo. J Cell Biochem. 2008, 103: 195-211. 10.1002/jcb.21403.View ArticlePubMed
- Zhao H, Deneau J, Che GO, Li S, Vagnini F, Azadi P, Sonon R, Ramjit R, Lee SM, Bojanowski K: Angelica sinensis isolate SBD.4: composition, gene expression profiling, mechanism of action and effect on wounds, in rats and humans. Eur J Dermatol. 2012, 22: 58-67.PubMed
- World Health Organization: WHO monographs on selected medicinal plants. Geneva. 1999
- Ma XQ, Duan JA, Zhu DY, Dong TT, Tsim KW: Species identification of Radix Astragali (Huangqi) by DNA sequence of its 5S-rRNA spacer domain. Phytochemistry. 2000, 54: 363-368. 10.1016/S0031-9422(00)00111-4.View ArticlePubMed
- Ma XQ, Shi Q, Duan JA, Dong TT, Tsim KW: Chemical analysis of Radix Astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations. J Agric Food Chem. 2002, 50: 4861-4866. 10.1021/jf0202279.View ArticlePubMed
- Fan TP, Yeh JC, Leung KW, Yue PY, Wong RN: Angiogenesis: from plants to blood vessels. Trends Pharmacol Sci. 2006, 27: 297-309. 10.1016/j.tips.2006.04.006.View ArticlePubMed
- Lei Y, Wang JH, Chen KJ: [Comparative study on angiogenesis effect of Astragalus membranaceus and Angelica sinensis in chick embryo choriollantoic membrane]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China J Chin Mater Med. 2003, 28: 876-878.
- Zhang Y, Hu G, Lin HC, Hong SJ, Deng YH, Tang JY, Seto SW, Kwan YW, Waye MM, Wang YT, Lee SM: Radix Astragali extract promotes angiogenesis involving vascular endothelial growth factor receptor-related phosphatidylinositol 3-kinase/Akt-dependent pathway in human endothelial cells. Phytother Res. 2009, 23: 1205-1213. 10.1002/ptr.2479.View ArticlePubMed
- Tang JY, Li S, Li ZH, Zhang ZJ, Hu G, Cheang LC, Alex D, Hoi MP, Kwan YW, Chan SW, Leung GP, Lee SM: Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC. PLoS One. 2010, 5: e11822-10.1371/journal.pone.0011822.PubMed CentralView ArticlePubMed
- Zhang Y, Hu G, Li S, Li ZH, Che OL, Hong SJ, Kwan YW, Chan SW, Leung GP, Lee SM: The pro-angiogenesis activity of astragaloside IV in HUVEC in vitro and zebrafish in vivo. Mol Med Report.
- Crawford AD, Esguerra CV, De Witte PA: Fishing for drugs from nature: zebrafish as a technology platform for natural product discovery. Planta Med. 2008, 74: 624-632. 10.1055/s-2008-1034374.View ArticlePubMed
- Flinn L, Bretaud S, Lo C, Ingham PW, Bandmann O: Zebrafish as a new animal model for movement disorders. J Neurochem. 2008, 106: 1991-1997. 10.1111/j.1471-4159.2008.05463.x.View ArticlePubMed
- Li ZH, Alex D, Siu SO, Chu IK, Renn J, Winkler C, Lou S, Tsui SK, Zhao HY, Yan WR, Mahady GB, Li GH, Kwan YW, Wang YT, Lee SM: Combined in vivo imaging and omics approaches reveal metabolism of icaritin and its glycosides in zebrafish larvae. Molecular BioSyst. 2011, 7: 2128-2138. 10.1039/c1mb00001b.View Article
- Hu G, Siu SO, Li S, Chu IK, Kwan YW, Chan SW, Leung GP, Yan R, Lee SM: Metabolism of calycosin, an isoflavone from Astragali Radix, in zebrafish larvae. Xenobiotica. 2012, 42: 294-303. 10.3109/00498254.2011.617015.View ArticlePubMed
- Masuko T, Minami A, Iwasaki N, Majima T, Nishimura S, Lee YC: Carbohydrate analysis by a phenol-sulfuric acid method in microplate format. Anal Biochem. 2005, 339: 69-72. 10.1016/j.ab.2004.12.001.View ArticlePubMed
- Blumenkrantz N, Asboe-Hansen G: New method for quantitative determination of uronic acids. Anal Biochem. 1973, 54: 484-489. 10.1016/0003-2697(73)90377-1.View ArticlePubMed
- Isogai S, Horiguchi M, Weinstein BM: The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev Biol. 2001, 230: 278-301. 10.1006/dbio.2000.9995.View ArticlePubMed
- Siekmann AF, Lawson ND: Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature. 2007, 445: 781-784. 10.1038/nature05577.View ArticlePubMed
- Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990, 5: 519-524.PubMed
- Klagsbrun M, D'amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996, 7: 259-270. 10.1016/S1359-6101(96)00027-5.View ArticlePubMed
- Zachary I: Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol. 2001, 280: C1375-C1386.PubMed
- Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999, 77: 527-543. 10.1007/s001099900019.View ArticlePubMed
- Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996, 380: 435-439. 10.1038/380435a0.View ArticlePubMed
- Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996, 380: 439-442. 10.1038/380439a0.View ArticlePubMed
- Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, Mcmahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59: 99-106.PubMed
- Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995, 376: 62-66. 10.1038/376062a0.View ArticlePubMed
- Bunnell SC, Henry PA, Kolluri R, Kirchhausen T, Rickles RJ, Berg LJ: Identification of Itk/Tsk Src homology 3 domain ligands. J Biol Chem. 1996, 271: 25646-25656. 10.1074/jbc.271.41.25646.View ArticlePubMed
This article is published under license to BioMed Central Ltd. 2012 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.